In an advanced online publication in the October issue of Nature Genetics, researchers report on the SEPS1 (Selenoprotein S) gene on chromosome 15 and how it regulates inflammation.

Apparently, the SEPS1 gene helps in ridding the cell of misfolded proteins, preventing it from accumulating and subsequently resulting to inflammation. In a Newswise report, one of the lead researchers, Ahmed Kissebah, said it provides new insight into studies he leads on the genetics of obesity:

"Now that we have identified SEPS1' role in inflammation, which is known to initiate the process of arterial wall hardening and the onset of Type 2 diabetes, we are developing an understanding of why obese persons with a faulty SEPS1 gene may be at higher risk of developing heart disease and diabetes."

Inflammation is a process involved in the pathology of several conditions such as cardiovascular disease, diabetes, obesity, preeclampsia, and various infectious diseases. Can SEPS1 be a potential target for gene therapy and/or drug development? ChemGenex Pharmaceuticals, who owns all intellectual property rights on this discovery, is already at its tails. Greg Collier, CEO, said

"...We have a strong portfolio of intellectual property related to SEPS1, and believe that this discovery may pave the way for future personalized medicine therapies to treat major diseases such as inflammation, diabetes and cancer. We are planning to screen for small molecules that alter SEPS1 activity with aim of partnering this program in the future."